Sii Investments Inc. WI boosted its position in Pfizer, Inc. (NYSE:PFE) by 1.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 161,061 shares of the biopharmaceutical company’s stock after buying an additional 2,573 shares during the period. Sii Investments Inc. WI’s holdings in Pfizer were worth $5,508,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the last quarter. Orrstown Financial Services Inc. boosted its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the last quarter. Cable Hill Partners LLC boosted its stake in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the last quarter. D Orazio & Associates Inc. boosted its stake in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the last quarter. Finally, Acropolis Investment Management LLC boosted its stake in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 100 shares during the last quarter. 70.10% of the stock is currently owned by institutional investors and hedge funds.

Pfizer, Inc. (PFE) traded down 0.51% on Friday, hitting $33.25. The stock had a trading volume of 12,928,473 shares. The stock has a market cap of $198.43 billion, a price-to-earnings ratio of 24.32 and a beta of 1.00. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.38. The stock’s 50 day moving average is $33.40 and its 200 day moving average is $33.31.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.64 earnings per share. Analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.85%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.

ILLEGAL ACTIVITY NOTICE: “Sii Investments Inc. WI Has $5.51 Million Stake in Pfizer, Inc. (PFE)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/sii-investments-inc-wi-has-5-51-million-stake-in-pfizer-inc-pfe/1479237.html.

PFE has been the topic of a number of analyst reports. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 10th. Barclays PLC reissued a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research note on Wednesday, May 3rd. Sanford C. Bernstein reissued a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research note on Wednesday, May 3rd. UBS AG reissued a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $37.77.

In related news, CEO Ian C. Read sold 96,950 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.